Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 26,661 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CTRL Clear all
Completed Phase 4 Interventional

Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus

NCT04951206
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
Fractionated CO2-laser, Clobetasol Propionate 0.05% Ointment
Device · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 2 Interventional Results available

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

NCT03999684
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
Tretinoin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Nov 9, 2026, 8:42 AM EST
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07450547
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
ANG003 Dose A, ANG003 Dose B, Creon
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
28
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 9, 2026, 8:42 AM EST
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04855747
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Levomecor Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
70
States / cities
Homewood, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 9, 2026, 8:42 AM EST
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

NCT07592858
View directory record Official record
Conditions
PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
University of Rhode Island
Other
Eligibility
25 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Louisville, Kentucky • Augusta, Maine
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Nov 9, 2026, 8:42 AM EST
Recruiting Phase 3 Interventional

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

NCT03659448
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
SGM-101
Drug
Lead sponsor
Surgimab
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Duarte, California • La Jolla, California • Weston, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 3 Interventional Results available

5% Topical Ibuprofen (IBU) for Ankle Sprain

NCT01945034
View directory record Official record
Conditions
Ankle Injuries
Interventions
Topical IBU twice daily, Placebo twice daily, Topical IBU three times daily, Placebo three times daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
19
States / cities
Sheffield, Alabama • Tucson, Arizona • Anaheim, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Nov 9, 2026, 8:42 AM EST
Terminated Not applicable Interventional Results available

Low-level Laser Therapy in Patients With Chronic Fibromyalgia

NCT02948634
View directory record Official record
Conditions
Chronic Pain
Interventions
Sham Phoenix Laser Treatment, Active Phoenix Laser Treatment
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Nov 9, 2026, 8:42 AM EST
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 3 Interventional

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

NCT00124332
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Nov 9, 2026, 8:42 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

NCT01372163
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05190457 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Trans Auricular Vagus Nerve Stimulation (taVNS) and Robotic Training for Paralyzed Arm After Stroke

NCT05339893
View directory record Official record
Conditions
Stroke, Hemiparesis
Interventions
In Motion Rehabilitation Robot
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 3 Interventional

Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain

NCT00226421
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone Extended Release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
31
States / cities
Hueytown, Alabama • Phoenix, Arizona • Colorado Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

NCT00763321
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
ABT-712, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
21 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
31
States / cities
Huntsville, Alabama • Burbank, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 2 Interventional

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure

NCT01251406
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Placebo, rhNRG-1 Dose 1, rhNRG-1 Dose 2
Drug
Lead sponsor
Zensun Sci. & Tech. Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01489306
View directory record Official record
Conditions
Drug Safety
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Nov 9, 2026, 8:42 AM EST
Completed Not applicable Interventional

Plantar Fasciitis Treated With Dynamic Splinting

NCT00650884
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Ankle Dorsiflexion Dynasplint System
Device
Lead sponsor
Dynasplint Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Sacramento, California • Orlando, Florida • Marietta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 3 Interventional Results available

Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients

NCT01271933
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Orange, California • Santa Ana, California • Ocala, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Nov 9, 2026, 8:42 AM EST
Terminated Phase 4 Interventional Results available

Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients

NCT00290238
View directory record Official record
Conditions
Low Back Pain
Interventions
Vertis Percutaneous Neuromodulation Therapy (PNT), Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
RS Medical
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • Eugene, Oregon + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Nov 9, 2026, 8:42 AM EST
Terminated Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

NCT04754334
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
ORMD-0801, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Nov 9, 2026, 8:42 AM EST
Completed Not applicable Interventional

Strengthening Skills Behavioral Intervention for Adults With Autism Spectrum Disorder

NCT04802434
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Strengthening Skills Program, PEERS Social Skills Program
Behavioral
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
21 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Nov 9, 2026, 8:42 AM EST
Terminated Phase 2 Interventional

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06118099
View directory record Official record
Conditions
Hidradenitis
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Fremont, California • Margate, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 3 Interventional Results available

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

NCT02627963
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Tivozanib hydrochloride, Sorafenib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 9, 2026, 8:42 AM EST
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 9, 2026, 8:42 AM EST